Quince Therapeutics, Inc. (QNCX)
NASDAQ: QNCX · Real-Time Price · USD
0.0952
-0.0036 (-3.64%)
At close: Mar 3, 2026, 4:00 PM EST
0.0914
-0.0038 (-3.99%)
Pre-market: Mar 4, 2026, 7:00 AM EST
Quince Therapeutics Employees
Quince Therapeutics had 36 employees as of December 31, 2024. The number of employees increased by 4 or 12.50% compared to the previous year.
Employees
36
Change (1Y)
4
Growth (1Y)
12.50%
Revenue / Employee
n/a
Profits / Employee
-$1,582,750
Market Cap
5.30M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 36 | 4 | 12.50% | 36 | 0 |
| Dec 31, 2023 | 32 | 11 | 52.38% | 32 | 0 |
| Dec 31, 2022 | 21 | -34 | -61.82% | 21 | 0 |
| Dec 31, 2021 | 55 | 17 | 44.74% | 55 | 0 |
| Dec 31, 2020 | 38 | 15 | 65.22% | 37 | 1 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| BiomX | 57 |
| Aptevo Therapeutics | 37 |
| Theriva Biologics | 22 |
| CalciMedica | 15 |
| XTL Biopharmaceuticals | 10 |
| Mustang Bio | 6 |
| Quoin Pharmaceuticals | 5 |
| Addex Therapeutics | 2 |
QNCX News
- 19 days ago - Quince Therapeutics Stock Plunges As Filing Shows Reverse Merger Plans, Bankruptcy Risks - Benzinga
- 21 days ago - Quince Therapeutics Stock Explodes 300% On Strategic Review - Benzinga
- 22 days ago - Quince Therapeutics Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Alternatives - Business Wire
- 4 weeks ago - Quince Therapeutics Announces Topline Results from Pivotal Phase 3 NEAT Clinical Trial of eDSP in Ataxia-Telangiectasia - Business Wire
- 4 weeks ago - Quince Therapeutics Presents Safety Data from Long-Term eDSP Treatment in Children with Ataxia-Telangiectasia at British Paediatric Neurology Association Annual Meeting - Business Wire
- 7 weeks ago - Quince Therapeutics: Good Potential In Orphan Disease In Q1 With Platform Potential - Seeking Alpha
- 2 months ago - Quince Therapeutics Announces Last Patient Last Visit in Phase 3 NEAT Clinical Trial in Patients with Ataxia-Telangiectasia - Business Wire
- 2 months ago - Quince Therapeutics Announces Publication of Use of eDSP in Early-Stage Clinical Studies in Pulmonary and Inflammatory Bowel Disorders - Business Wire